“Contrary to popular misconception,” the pharmaceutical industry in New Zealand has no intention of using the Trans Pacific Partnership (TPP) process to get rid of the nation’s drugs-buying agency PHARMAC, an industry leader has stated. However, “New Zealanders could have access to better and newer medicines if the system was streamlined and the broader questions relating to health policy and relative spend were addressed,” added Heather Roy, chair of industry group Medicines New Zealand, speaking at TPP meetings in Dallas, USA.
